Company: JUNS
Filing Date: 2025-10-28
Form Type: PRER14A
Source: 0001493152-25-019793
Chunk: 84

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-10-28
Form: PRER14A
Chunk 84
---
 24, 2025, subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of the SEPA. The issuance of such shares could also have a dilutive effect on our book value per share and on any future earnings per share, and the sale or any resale of such shares could cause prevailing market prices for our Common Stock to decline.

However, we cannot predict the substance of
any future Advances or the market price of our Common Stock at any future date and, therefore, we cannot predict the actual number of
shares of Common Stock that will be issued under the SEPA or upon conversion of any Convertible Notes. Because the number of shares of
Common Stock that may be issued to Yorkville pursuant to the SEPA and upon conversion of the Convertible Notes is determined based on
the market price at the time of issuance, the exact magnitude of the dilutive effect cannot be conclusively determined. However, the
dilutive effect may be material to our current stockholders.

Possible Effects of Disapproval of this Proposal

If this Proposal No. 5 is not approved by our stockholders at the Annual Meeting, it may impair our working capital and our ability to fund capital expenditures, operating expenses and the selective pursuit of business development opportunities, including continued product or technology investment. Should the proposal fail to receive approval from the stockholders, the Company may be compelled to explore alternative financing options that are less advantageous and potentially more dilutive. Our Board has determined that the SEPA, with such modifications, amendments, or changes (consistent with the intent and purpose of this proposal) agreed upon by the parties to the SEPA, and in accordance with the stockholder approval requirements of Nasdaq Listing Rules 5635(b) and 5635(d) is in the best interests of us and our stockholders because the flexibility to issue common stock in excess of the Exchange Cap provides us with a reliable source of capital for working capital and general corporate purposes.

Potential Adverse Effects of Approving this Proposal

If approved, this proposal will provide for the issuance of up to an aggregate of up to $20 million shares of Common Stock to the Yorkville at prices that are below the Nasdaq’s minimum price requirements. The issuance of shares of Common Stock to the Yorkville will dilute the percentage ownership interest of all stockholders, may dilute the book value per share of the Common Stock and will increase the number of